Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: A case report

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 3, 2008, Pages 318-320

  Rahier, J F ^a   Rahier, J ^a   Leclercq, I ^a   Geubel, A P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Atorvastatin; Bile duct injury; Cholestatic hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; BLOOD CLOTTING FACTOR 5; GLIQUIDONE; INSULIN; METFORMIN; RIFAMPICIN; URSODEOXYCHOLIC ACID;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; ECHOGRAPHY; FATTY LIVER; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFLAMMATORY INFILTRATE; INTENSIVE CARE UNIT; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; LIVER LEVEL; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PORTUGAL; PRURITUS;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; BILE DUCTS; CHOLESTASIS; HEPATITIS, TOXIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES;

EID: 58149507709     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. CLARKE A.T., MILLS P.R. Atorvastatin associated liver disease. Digestive and liver disease. 2006, 38: 772-777.
2. GEOGHEGAN M., SMITH V., GREEN J.R.B. Acute cholestatic hepatitis associated with atorvastatin. Gut, 2004, 53 (Suppl. III): A123.
3. PERGER L., KOHLER M., FATTINGER K., FLURY R., MELER P.J., PAULI-MAGNUS C. Fatal liver failure with atorvastatin. J. Hepatol., 2003, 39 (6): 1095-7.
4. BABICH M.M., PIKE I., SHIFFMAN ML. Metformin-induced acute hepatitis. Am. J. Med., 1998, 104: 490-2.
5. DEUTSCH M., KOUNTOURAS D., DOURAKIS S.P. Metformin hepatotoxicity. Ann. Intern. Med., 2004, 140: 25.
6. DESILETS D.J., SHORR A.F., MORAN K.A., HOLTZMULLER K.C. Cholestatic jaundice associated with the use of metformin. Am. J. Gastroenterol., 2001, 96: 2257-8.
7. NAMMOUR F.E., FAYAD N.F., PEIKIN S.R. Metformin-induced cholestatic hepatitis. Endocr. Pract., 2003, 9: 307-9.
8. CHAN K.A., TRUMAN A., GURWITZ J.H., HURLEY J.S., MARTINSON B., PLATT R., EVERHART J.E., MOSELEY R.H., TERRAULT N., ACKERSON L., SELBY J.V. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch. Intern. Med., 2003, 163: 728-34.
9. BLACK D.M., BAKKER-ARKEMA R.G., NAWROCKI J.W. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Archives of Internal Medicine, 1998, 158 (6): 577-84.
10. NEWMAN C.B., PALMER G., SILBERSHATZ H., SZAREK M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am. J. Cardiol., 2003, 92: 670-6.
11. NAKAD A., BATAILLE L., HAMOIR V., SEMPOUX C., HORSMANS Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet, 1999, 353(9166): 1763-4.
12. PELLI N., SETTI M., CEPPA P., TONCINI C., INDIVERI F. Autoimmune hepatitis revealed by atorvastatin. Eur. J. Gastroenterol. Hepatol., 2003, 15: 921-924.
13. HAUTEKEETE M.L., HORSMANS Y., VAN WAEYENBERGE C., DEMANET C., HENRION J., VERBIST L., BRENARD R., SEMPOUX C., MICHIELSEN P.P., YAP P.S., RAHIER J., GEUBEL A.P. HLA association of amoxicillin-clavulanate - induced hepatitis. Gastroenterology, 1999 Nov, 117 (5): 1181-6.